TABLE 2.

Protective efficacy of DW286 on systemic infections in mice

Microorganism [challenge dose (CFU/ml)] and compounda	MIC (μg/ml)	PD50b (mg/kg)	95% Confidence limits
S. aureus Smith [1.2 × 107]
DW286	0.004	0.12	0.08-0.17
Ciprofloxacin	0.5	3.43	2.40-4.89
Gemifloxacin	0.031	0.77	0.39-1.51
Sparfloxacin	0.063	0.54	0.33-0.89
Trovafloxacin	0.016	0.32	0.16-0.64
MRSA MB4-19 [3.1 × 108]
DW286	0.004	0.12	0.07-0.20
Ciprofloxacin	0.25	3.99	2.12-7.53
Gemifloxacin	0.016	0.70	0.39-1.26
Sparfloxacin	0.031	0.22	0.11-0.42
Trovafloxacin	0.016	0.17	0.10-0.28
QRSA MB4-20 [5.0 × 108]
DW286	0.25	5.83	3.13-10.87
Ciprofloxacin	32	>40
Gemifloxacin	2	>40
Sparfloxacin	32	>40
Trovafloxacin	8	>40
S. pyogenes ATCC 8668 [1.5 × 107]
DW286	0.008	0.12	0.07-0.20
Ciprofloxacin	0.25	15.00	7.82-28.77
Gemifloxacin	0.016	1.02	0.68-1.54
Sparfloxacin	0.25	13.36	5.14-34.71
Trovafloxacin	0.063	1.71	0.85-3.44
S. pneumoniae MB4-21 [1.1 × 105]
DW286	0.008	0.19	0.10-0.38
Ciprofloxacin	0.5	10.05	5.31-19.04
Gemifloxacin	0.016	0.33	0.21-0.51
Sparfloxacin	0.125	1.80	0.99-3.28
Trovafloxacin	0.031	2.32	1.26-4.29
E. coli MB4-01 [6.6 × 107]
DW286	0.008	0.37	0.12-1.09
Ciprofloxacin	0.016	0.32	0.11-0.88
Gemifloxacin	0.008	0.26	0.10-0.71
Sparfloxacin	0.008	0.52	0.32-0.82
Trovafloxacin	0.008	0.84	0.47-1.51
P. aeruginosa MB4-16 [9.8 × 104]
DW286	1	6.29	3.23-12.24
Ciprofloxacin	0.125	0.94	0.46-1.93
Gemifloxacin	0.25	4.47	2.49-8.05
Sparfloxacin	0.25	2.56	1.19-5.50
Trovafloxacin	0.5	3.15	1.61-6.15
K. pneumoniae MB4-02 [1.3 × 105]
DW286	0.125	0.50	0.28-0.90
Ciprofloxacin	0.031	0.19	0.10-0.37
Gemifloxacin	0.125	0.55	0.31-0.98
Sparfloxacin	0.125	0.17	0.11-0.28
Trovafloxacin	0.125	0.26	0.16-0.42

^aEach test compound was administered once orally to mice immediately postinfection.

^bThe number of survivors on day 7 postinfection was used to calculate the PD₅₀ by Litchfield and Wilcoxon's method (P < 0.05).